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This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of
Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex®, nabiximols) in combination with
cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole).
Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two
treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of
the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor
omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC).
A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg)
reduced the Cmax and AUC of all analytes. Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%)
and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration
of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing
the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92
ng/mL (+204%). No significant deviations in Cmax or AUC for any analyte were observed when THC/CBD spray was
co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in
combination with rifampicin, ketoconazole and omeprazole.
Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all
analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to
be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential
effects should be taken into consideration when co-administering THC/CBD spray with compounds which share
the CYP3A4 pathway such as rifampicin or ketoconazole.
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The endocannabinoid system modulator Δ9-tetrahydro-
cannabinol (THC)/cannabidiol (CBD) oromucosal spray
(Sativex®, nabiximols) has been reported to be effective
in relieving a number of multiple sclerosis (MS) symp-
toms including spasticity, central neuropathic pain and
bladder dysfunction (Rog et al. 2005; Johnson et al. 2010;
Rog et al. 2007), and has recently been approved in vari-
ous European countries and abroad (i.e. in Canada,
Israel, New Zealand) as add-on treatment for spasticity
in MS patients. Other potential indications for this com-
pound include pain relief in advanced cancer (Johnson
et al. 2010; Porteney et al. 2012), as well as peripheral
neuropathic pain in MS (Nurmikko et al. 2007). Derived
from proprietary cannabis plant varieties bred to exhibit
a pre-determined content of cannabinoids (CBs), THC/
CBD spray is fully standardized and contains two princi-
pal CBs, THC and CBD at an approximately 1:1 ratio as
well as minor amounts of other CBs and non-CB com-
ponents. The specified CBs constitute at least 90% of the
total CB content of the extract, however, the minor CBs
and other constituents also contribute to the therapeutic
profile of THC/CBD spray (Russo 2011), and may be in-
volved in stabilizing the extract (Whittle et al. 2001).
CBs are thought to act primarily via activation of spe-
cific CB receptors, CB1 and CB2 (Howlett et al. 2002).
CB1 is predominantly expressed in the central nervous
system (CNS), while CB2 is primarily expressed in the
periphery, especially in immune cells (Pertwee 2007).
Endogenous ligands (“endocannabinoids”) produced in
mammalian tissues target these receptors, and together
with the catabolic and metabolic enzymes and transporter
systems they constitute the endocannabinoid system.
Multiple drug therapy is often used with a single pa-
tient. As THC/CBD spray is indicated for MS and po-
tentially advanced cancer pain, the likelihood is high
that patients would be receiving different concomitant
medications. As such, drug-drug interactions could
occur which affect the bioavailability of THC/CBD spray
through absorption, metabolism or disposition. In turn
this could affect the treatment and adverse events (AEs)
experienced by the patient (Chen & Raymond 2006). In
some incidences, AEs experienced due to drug-drug inter-
actions can be life-threatening, therefore understanding
the mechanisms of these interactions is important so that
dosing and safety information can be adjusted accordingly.
Cytochrome P450 (CYP450) is a family of isoenzymes
responsible for the biotransformation of several drugs,
and drug metabolism via this system has emerged as an
important determinant of the occurrence of several
drug-drug interactions that can result in toxicity, re-
duced pharmacological effect and AEs (Guengerich
2008). Determining whether the drugs involved act as
enzyme substrates, inducers, or inhibitors can preventclinically significant interactions from occurring. More-
over, avoiding co-administration or adjusting a patient's
drug regimen early in the course of therapy can provide
optimal response with minimal AEs (Ogu & Maxa 2000).
Many different CYP450 isoenzymes have been identified
to-date, including six which play important roles in drug
metabolism (DiPiro 1999; Cupp & Tracy 1998): CYP1A2,
CYP2C19, CYP2C9, CYP2D6, CYP2E1, and CYP3A4.
CYP450 inhibitors and inducers are known to affect
the metabolism of THC. Previous literature reports have
indicated that CBs, especially THC, are metabolized by
CYP3A4, 2C9, 2C19 and possibly 2D6 in humans
(Huestis 2007), and that the primary metabolites of
THC and CBD are 11-hydroxy-THC (11-OH-THC) and
7-hydroxy-CBD, respectively (Huestis 2007). The forma-
tion of 11-OH-THC has been reported to be primarily
catalysed by CYP2C19 and 2C9 (Bland et al. 2005).
In vitro studies of THC and CBD on CYP450 induc-
tion and inhibition indicate that both inhibit CYP1A1,
1A2 and 1B1 enzymes (Yamaori et al. 2010). CBD also
has an inhibitory effect on CYP3A4 and CYP2C19.
However, this effect only occurred at high concentra-
tions (IC50 = 6-9 μM) of CBD (GW unpublished data),
and in normal dosing, peak plasma concentrations of
CBD are approximately 5 ng/mL or less, 400-fold lower
than the levels at which CYP inhibition may be antici-
pated. As such, it is unlikely that THC/CBD spray would
cause a relevant inhibition of CYP450s. However, to in-
vestigate the potential interactions of THC and CBD
with drugs which also interact with the CYP450s
CYP3A4 and CYP2C19, various known inducers/inhi-
bitors of these isoenzymes were employed and the
pharmacokinetics (PKs) of their co-administration with
THC/CBD spray evaluated.
Rifampicin is an antibiotic drug, a strong inducer of
CYP3A4 and moderate inducer of CYPs 2C19, 2B6, 2C8
and 2C9, and has been extensively used in clinical stud-
ies as a prototypical inducer of these enzymes (Division
of Clinical Pharmacology 2012; Federal Drug Association
2012). Ketoconazole is a synthetic antifungal drug, is a
strong inhibitor of CYP3A4 (Federal Drug Association
2012), and a weak inhibitor of CYPs 2C8 and 2C19
(Federal Drug Association 2012). Omeprazole is a
proton-pump inhibitor which is primarily metabolized
by, and demonstrates high affinity for CYP2C19 (Furuta
et al. 2005), and is also a moderate inhibitor of 2C19
(Federal Drug Association 2012). This study investigated
the potential interaction of these CYP450 inhibitors/in-
ducers on the PK and safety profile of THC/CBD spray
in healthy male subjects.
Methods
This open-label, randomized, crossover, drug-interaction
study took place at one study site in the UK (Quintiles
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Guy's Research Ethics Committee, and was conducted
according to the International Conference on Harmon-
isation guidelines on Good Clinical Practice and the eth-
ical principles stated in the Declaration of Helsinki and
local UK regulations. All participants gave written in-
formed consent.
Study design and treatment groups
A total of 36 healthy males subjects enrolled and were
divided into three groups of 12. Within each group par-
ticipants were randomized to one of two treatment se-
quences with six subjects receiving each sequence.
Subjects received four sprays of THC/CBD spray (10.8/
10 mg) alongside single usual daily doses of either rifam-
picin (600 mg), ketoconazole (400 mg) or omeprazole
(40 mg) according to the following sequences, designed
with a time-frame that was standard and fitting to the
aims of this study:
Sequence 1A. Subjects received a single dose of 4
sprays THC/CBD on Day 1 and once daily
rifampicin on Days 2-10. Subjects then received
both THC/CBD spray and rifampicin on Day 11.
Sequence 1B. Subjects received rifampicin on Days 1-9.
Subjects received THC/CBD spray and rifampicin
on Day 10 and then a single dose of 4 sprays THC/
CBD on Day 18.
Sequence 2C. Subjects received a single dose of 4
sprays THC/CBD on Day 1 and once daily
ketoconazole on Days 2-5. Subjects then received
both THC/CBD spray and ketoconazole on Day 6.
Sequence 2D. Subjects received ketoconazole on Days
1-4. Subjects received THC/CBD spray and once
daily ketoconazole on Day 5. Subjects then received
a single dose of 4 sprays THC/CBD on Day 10.
Sequence 3E. Subjects received a single dose of 4
sprays THC/CBD on Day 1. Subjects received once
daily omeprazole on Days 2-6, and then THC/CBD
spray and omeprazole on Day 7.
Sequence 3F. Subjects received a once daily dose of
omeprazole on Days 1-5. Subjects received both
THC/CBD spray and omeprazole on Day 6. Subjects
then received a single dose of 4 sprays THC/CBD
on Day 9.
Blood sampling procedure and plasma preparation
Blood samples were collected at specified times and
stored on ice (except rifampicin PK samples which were
stored in iced water) prior to processing and storage.
Plasma samples were separated by centrifugation (ap-
proximately 2500 rpm × 15 minutes at 4°C). Samples
were stored in 4 mL amber glass screw top glass vials
with PTFE lined screw caps labelled with Guys DrugResearch (Quintiles Limited) labels. The aliquots were
stored in clearly labelled containers in a freezer set at or
below -20°C, until shipped for assay. Samples were
shipped on dry ice at the appropriate time-points.
Analysis method
The assay validation was undertaken by Advanced
Bioanalytical Service Laboratories (London, UK), who
developed the technique after reviewing the literature,
which was based on the methodology adopted by three
different groups (Foltz et al. 1983; Goodall & Basteyns
1995; Kemp et al. 1995), and designed with reference to
FDA guidelines for industry (FDA Guidance for Industry
2012). The method utilised protein precipitation, solvent
extraction and derivatisation for the sample preparation
and then sample analysis by capillary gas chromatog-
raphy and detection by a mass spectrometer (GC-MS).
The validation procedure investigated the calibration
model with the best regression fit over the concentration
range 0.1 - 100 ng/mL for CBD, THC and 11-OH-THC,
as well as precision and accuracy of the method, stabil-
ity, carry-over, and specificity.
Human plasma from healthy volunteers was used to
prepare the standards and quality control (QC) samples,
with analytes extracted using hexane/ethyl acetate (7:1
ratio), derivatised with N,O-Bis(trimethylsilyl)trifluoroa-
cetamide. Analytic grade THC (Sigma, UK), CBD
(Sigma, UK) and 11-OH-THC (Radian International and
Cerillant, UK) were obtained, and three sets of CBD,
THC and 11-OH-THC were used to support the study.
Deuterated THC-d3 (Sigma, UK) was used as the in-
ternal standard. The GC-MS equipment was a Hewlett
Packard 6890 Gas Chromatograph attached to a Hewlett
Packard 5973 Mass Selective Detector. Data handling
was carried out using an MS Chemstation System and
the peak area ratio of the analytes to the internal stand-
ard was calculated in Excel (2000). The concentrations
were calculated from the ratio data using least squares
ln(y) on ln(x) regression performed in Excel (2000), and
were then checked manually. Regression analysis was
undertaken to find the regression model that best de-
scribed the calibration data (for details, see (Miller &
Miller 1992)).
Intra-assay precision and bias was examined using
spiked control samples analysed in replicates of five.
Inter-assay precision and accuracy were analysed in
quintuplet at three concentrations and on three separate
occasions.
The lowest and upper Limits of Quantification (LOQ)
were investigated by looking at five (500 μL) plasma
samples containing 0.10 ng/mL and 100.0 ng/mL
(the lowest and highest calibrators) of THC, CBD and
11-OH-THC, assayed in one batch, possessing accept-
able precision and accuracy. As such, these lowest and
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of these analytes in human plasma over these concentra-
tion ranges.
The inter- and intra-assay accuracy of the assay calcu-
lated for THC was -0.53, -0.45, -1.72% and -0.50, -2.10, -
0.86% at plasma THC concentrations of 2.0, 20.0 and
80.0 ng/mL, respectively. The inter- and intra-assay pre-
cision of the assay calculated for THC was 1.88, 2.51,
2.41% and 2.64, 1.09, 1.29% at plasma THC concentra-
tions of 2.0, 20.0 and 80.0 ng/mL, respectively.
The inter- and intra-assay accuracy of the assay calcu-
lated for CBD was -2.90, 0.81, 1.78% and -2.00, -0.75,
2.38% at plasma CBD concentrations of 2.0, 20.0 and
80.0 ng/mL, respectively. The inter- and intra-assay pre-
cision of the assay calculated for CBD was 4.05, 2.28,
2.31% and 6.67, 1.43, 1.08% at plasma CBD concentra-
tions of 2.0, 20.0 and 80.0 ng/mL, respectively.
The inter- and intra-assay accuracy of the assay calcu-
lated for 11-OH-THC was 0.00, 0.20, -3.44% and -0.46, -
0.05, -1.43% at plasma 11-OH-THC concentrations of
2.17, 21.70 and 86.80 ng/mL, respectively. The inter-
and intra-assay precision of the assay calculated for
11-OH-THC was 3.45, 3.44, 2.57% and 6.04, 1.96, 1.24%
at plasma 11-OH-THC concentrations of 2.17, 21.70 and
86.80 ng/mL, respectively.
Extraction procedure
A 0.5 mL aliquot of test sample, QC or blank plasma
was placed into a test tube. The blank plasma was spiked
with 50 μL of the appropriate standard solution to pro-
duce the calibration standards. 50 μL of the internal
standard was added to each test tube. The samples were
then diluted by the addition of 500 μL of 0.1% (w/v) as-
corbic acid and the protein precipitated by the addition
of 1.0 mL of acetonitrile. The proteins were removed by
centrifugation and the supernatant concentrated to 1
mL using nitrogen at 50ºC. The samples were then basi-
fied by the addition of 300 μL of 5M sodium hydroxide
and the analytes extracted by the addition of 2.0 mL of
7:1 hexane:ethyl acetate. After mixing for 16 minutes the
tubes were centrifuged and the top layer transferred into
clean 3 dram vials. The solvent was removed using ni-
trogen at 70ºC and the dried extract resuspended in 100
μL of BSTFA and transferred to microvials, capped and
placed at 70ºC for 30 minutes to derivatise the analytes.
The microvials were then cooled and loaded onto the
autosampler tray for analysis where 1 μL was injected
onto the GC-MS system.
Inclusion and exclusion criteria
Inclusion criteria
Eligible subjects were healthy males between 18 and 45
years of age with a Body Mass Index (BMI) of between
18 and 30 Kg/m2. Subjects had no clinically significantabnormal findings upon physical examination, 12-lead
electrocardiogram (ECG), medical history, clinical la-
boratory at screening, or renal and hepatic function.
Subjects were non-users of tobacco products and were
negative for Human Immunodeficiency Viruses I and II,
Hepatitis B surface antigen, and antibodies to the Hepa-
titis C virus. Eligible subjects had a negative urine screen
for alcohol, drugs of abuse (screening only) and cotinine,
and were using an appropriate barrier method of contra-
ception in addition to a second method of barrier
contraception being used by their partner for the study
duration and for three months following administration
of THC/CBD spray.
Exclusion criteria
Subjects with a history of significant cardiovascular, pul-
monary, hepatic, renal, haematologic, gastrointestinal,
endocrine, immunologic, dermatologic, neurologic, or
psychiatric disorder were excluded. Those with a history
of alcohol or drug abuse within two years of the study
were also excluded; however, those with a history of pre-
vious cannabis use were not excluded if willing to ab-
stain for the study duration, unless they had used
cannabis or CB-based medicine within 30 days prior to
receiving study medication. Subjects with an abnormal
diet, who had made substantial changes to eating habits
in the 30 day period prior to the study, or who had par-
ticipated in another clinical trial in the 90 day period
prior to study entry were also excluded. Subjects who
used any prescription or over the counter medication
within 14 and seven days of study onset, or during the
study, respectively, were also excluded, as were subjects
who had treatment with any known enzyme-altering
agents within 30 days prior to or during the study. In
addition, subjects who had a postural drop of 20 mmHg
or more in systolic blood pressure at screening were ex-
cluded, as were subjects who had donated blood or
plasma within 90 days of study initiation. Subjects with a
known history of hypersensitivity or idiosyncratic reac-
tion to the study drug or related compounds were also
excluded.
Concomitant medication
If concomitant medication was taken during the study, a
joint decision was be made by the investigator and spon-
sor if the subject should continue in the study. No sub-
ject was permitted to take medication during the time of
sample collection.
Dietary restrictions
Xanthines and alcohol were prohibited 48 hours prior to
dosing days and throughout each period of sample col-
lection. Grapefruit was prohibited 10 days prior to initial
dosing and throughout the study.
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Pharmacokinetic endpoints
The PK endpoints were mean peak plasma concentra-
tion (Cmax), area under the plasma concentration versus
time curve (AUC), from time 0 to the last measurable
concentration (AUC(0-t)), AUC to infinite time (AUC(0-
inf )), time to peak plasma concentration (Tmax), half-time
(t1/2), elimination rate constant (Kel), oral clearance
(CL/F) and apparent volume of distribution following
oral administration (Varea/F; THC and CBD only) of
THC, 11-OH-THC and CBD following administration of
THC/CBD spray alone or THC/CBD spray concomi-
tantly with rifampicin, ketoconazole, and omeprazole.
Safety endpoints
The safety endpoints were blood pressure, heart rate,
ECG, clinical laboratory data (haematology and bio-
chemistry), urinalysis, AEs and concomitant medica-
tions, recorded at each visit.
Statistical methods
Sample size
A total of 36 subjects were planned and analyzed, with
12 subjects in each treatment group. However, there was
no formal sample size power calculation for this study.
PK parameters
Summary statistics of PK parameters and concentrations
included all treated subjects. Only subjects completing
the study (i.e. PK data available for THC/CBD spray and
THC/CBD spray plus interacting drug), were included in
the statistical analyses of the interaction effects of rifam-
picin (Group 1), ketoconazole (Group 2), and omepra-
zole (Group 3). Data from the 3 groups were analyzed
separately and no comparisons were made between
groups. For each group, the PK parameters Cmax, AUC(0-
t) and AUC(0-inf ) were statistically analyzed using an
analysis of variance model (ANOVA, SAS PROC
MIXED). The traditional two-period crossover design
was implemented. The model included effects of treat-
ment, period, sequence, and subject within sequence.
The log-transformed AUC and Cmax data was analyzed
using a general linear mixed model. The model included
fixed terms for treatment, sequence, period and a ran-
dom term for subject within sequence. Point estimates
and 90% confidence intervals (CIs) for the ratios of the
treatment means were calculated. The two one-sided hy-
potheses were tested at a 5% level for Cmax, AUC(0-t) and
AUC(0-inf ) by constructing 90% CIs for the ratio of the
treatment means. The 90% CIs were obtained from the
antilogarithms of the lower and upper bounds of the
90% CIs for the differences in the least-squares means of
the log-transformed data. No significant interaction with
respect to the log-transformed Cmax, AUC(0-t) and AUC(0-inf ) was concluded if the 90% CI of the ratio of the
geometric means fell within the range of 0.80 to 1.25.
The summaries and descriptive statistics were calculated
using WinNonlin® Professional, version 4.1b and SAS®,
version 9.1.
Results
Mean participant ages for sequences 1A, 1B, 2C, 2D, 3E,
and 3F were 28.8, 25.8, 32.5, 23.7, 26.5 and 27.0 years of
age, respectively. Mean BMIs for the same respective se-
quences were 26.2, 24.2, 26.8, 25.2, 23.3 and 24.3 Kg/m2,
giving a similar demographic profile across treatment
groups.
Plasma concentrations and exposure
Mean plasma concentration versus time curves for
THC, CBD and 11-OH-THC following administration of
THC/CBD sprays alone and in combination with rifam-
picin, ketoconazole or omeprazole, are presented in
Figures 1, 2 and 3, respectively.
Based on group mean Cmax and AUC, the plasma ex-
posure of THC, CBD and 11-OH-THC decreased for all
three analytes following a single dose (4 sprays) of THC/
CBD administered at the end of a 10-day dosing period
(repeated dosing over 10 days) with rifampicin, com-
pared with the PK parameters following a single dose of
THC/CBD alone (4 sprays, no rifampicin). The decrease
was general, occurring in 82-100% of subjects (Table 1).
For the ketoconazole treatment group, mean Cmax and
AUC increased for all three analytes following a single
dose of THC/CBD (4 sprays) administered at the end of
a 5-day dosing period with ketoconazole compared with
the PK parameters following a single dose of THC/CBD
alone (4 sprays, no ketoconazole). The increase was also
general, occurring in 63-100% of the subjects (Table 2).
Following single dose administration of THC/CBD
spray (4 sprays) at the end of a 6-day dosing period with
omeprazole, the plasma concentrations and PK parame-
ters were similar for THC, marginally higher for CBD
and marginally lower for 11-OH-THC compared with
the PK parameters following a single dose of THC/CBD
alone (4 sprays, no omeprazole) (Table 3).
Oral clearance
The mean CL/F of THC/CBD spray increased from
1207 L/h to 1595 L/h (+32%) for THC and from 2817 L/
h to 5966 L/h (+112%) for CBD after multiple dose ri-
fampicin treatment (Table 1). Conversely, the mean CL/
F of THC/CBD spray decreased from 1504 L/h to 920
L/h (-39%) for THC and from 2998 L/h to 1731 L/h
(-42%) for CBD when co-administered with ketocona-
zole (Table 2). No significant differences in CL/F for
























































































Figure 1 Mean (+SD) plasma concentrations of THC (a), CBD (b) and 11-OH-THC (c) over time after administration of a single dose
(4 sprays) of THC/CBD (n = 11) or THC/CBD spray in combination with multiple dose (2 x 300 mg) administration of Rifampicin
(n = 12).


























































































Figure 2 Mean (+SD) plasma concentrations of THC (a), CBD (b) and 11-OH-THC (c) over time after administration of a single dose
(4 sprays) of THC/CBD (n = 11) or THC/CBD spray in combination with multiple dose (2 x 200 mg) administration of Ketoconazole
(n = 11).


























































































Figure 3 Mean (+SD) plasma concentrations of THC (a), CBD (b) and 11-OH-THC (c) over time after administration of a single dose
(4 sprays) of THC/CBD (n = 11) or THC/CBD spray in combination with multiple dose (2 x 20 mg) administration of Omeprazole
(n = 12).
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Table 1 Summary of pharmacokinetic parameters of THC,
CBD and 11-OH-THC after a single dose of THC/CBD
(4 sprays) alone or in combination with rifampicin
Parameter THC/CBD spray alone
(n = 12)
THC/CBD spray and
rifampicin (n = 12)
THC
AUC(0-t) (h*ng/mL) 9.10 (2.98) 6.53 (2.70)
AUC(0-inf) (h*ng/mL) 9.86 (3.35)
a 7.53 (2.99)
Cmax (ng/mL) 2.94 (1.21) 1.88 (1.07)
Tmax (h) 1.01 (0.50-6.02) 1.75 (1.25-2.57)
Kel (h-1) 0.197 (0.093)a 0.189 (0.071)
t½ (h) 4.68 (3.42)
a 4.93 (3.91)
CL/F (L/h) 1207 (373)a 1595 (473)
Varea/F (L) 7625 (4326)a 10297 (5888)
CBD
AUC(0-t) (h*ng/mL) 3.23 (2.13) 1.31 (0.89)
AUC(0-inf) (h*ng/mL) 5.10 (3.06) 2.15 (0.94)
b
Cmax (ng/mL) 1.03 (0.81) 0.50 (0.37)
Tmax (h) 1.00 (0.50-4.00) 1.50 (1.00-6.00)
Kel (h-1) 0.148 (0.108) 0.196 (0.092)b
t½ (h) 10.86 (12.71) 4.13 (1.65)
b
CL/F (L/h) 2817 (1913) 5966 (3713)b
Varea/F (L) 28312 (19355) 34790 (20036)b
11-OH-THC
AUC(0-t) (h*ng/mL) 18.61 (7.81) 1.84 (0.79)
AUC(0-inf) (h*ng/mL) 21.59 (8.76) 2.78 (0.68)
c
Cmax (ng/mL) 3.38 (1.95) 0.45 (0.18)
Tmax (h) 1.38 (0.50-6.02) 1.75 (1.50-2.57)
Kel (h-1) 0.083 (0.042) 0.189 (0.074)c
t½ (h) 9.88 (3.89) 4.19 (1.62)
c
Data presented are mean and (SD) except for Tmax where median and range
are shown, an=11; bn=10; cn=11.
Stott et al. SpringerPlus 2013, 2:236 Page 9 of 15
http://www.springerplus.com/content/2/1/236administered with omeprazole compared to THC/CBD
spray alone (Table 3).
Tmax and t½
A small increase in median Tmax for all analytes was ob-
served when THC/CBD spray was co-administered with
rifampicin (respective % changes for THC, CBD and
11-OH-THC of +73%, +50% and +27%) (Table 1). There
was no change in the mean t1/2 of THC, but a general
decrease for CBD and 11-OH-THC was observed (re-
spective % changes for THC, CBD and 11-OH-THC of
+5%, -62% and -58%) (Table 1). When THC/CBD spray
was co-administered with ketoconazole, there was a
small increase in mean Tmax for 11-OH-THC and CBD,
but no trend was observed for THC when looking at in-
dividual data (respective % changes for THC, CBD and
11-OH-THC of +17%, +27% and +50%) (Table 2). Therewas no change in the t1/2 of THC or CBD, but a general
decrease for 11-OH-THC from 9.51 (THC/CBD spray
alone) to 7.48 h (THC/CBD spray and ketoconazole)
was observed (respective % changes for THC, CBD and
11-OH-THC of +44%, -16% and -21%) (Table 2). When
THC/CBD spray was co-administered with omeprazole,
the t1/2 and Tmax for all analytes were similar to respect-
ive THC/CBD spray alone values (respective % changes
in t1/2 for THC, CBD and 11-OH-THC of -11%, +5%
and +9%; respective % changes in Tmax for THC, CBD
and 11-OH-THC of 0%, +9% and -24%%) (Table 3).
Elimination rate constant
Kel was estimated over a short sampling period (less
than two t1/2s) for the majority of CBD and 11-OH-THC
profiles, and the regression had low precision (rsq ad-
justed <0.7) in a few profiles. Furthermore, AUC(0-inf) had
an extrapolated area larger than 20% for several CBD pro-
files (Table 1).
90% confidence intervals
Following co-administration of THC/CBD spray with ri-
fampicin or ketoconazole, the 90% CIs for the geometric
mean ratios of Cmax, AUC(0-t) and AUC(0-inf ) did not fall
within the pre-defined “no interaction” range of 0.80 to
1.25 for any of the analytes (Table 4).
Following co-administration of THC/CBD spray with
omeprazole, for THC and CBD the upper limit of the
90% CI of the geometric mean ratio of Cmax was above
1.25. The AUC(0-t) and AUC(0-inf ) 90% CI upper limits
were above 1.25 and the lower limits were below 0.80
for THC and CBD (Table 4). For 11-OH-THC the lower
limits of the 90% CI of Cmax, AUC(0-t) and AUC(0-inf )
were below 0.80, did not fall within the pre-defined “no
interaction” range of 0.80 to 1.25 (Table 4).
Inter-subject variability
The Cmax and AUC % Co-efficient of Variation (CV%)
ranges were similar for all analytes in all treatment
groups with the exception of a higher CV% for THC
when THC/CBD spray was administered alone in the
THC/CBD spray alone or in combination with omepra-
zole treatment group.
THC/CBD spray in combination with rifampicin had a
CV% of 25-74% and for THC/CBD spray alone the CV%
was 33-79% for all analytes. THC/CBD spray in combin-
ation with ketoconazole had a CV% of 34-87% and for
THC/CBD spray alone this was 23-69% for all analytes.
THC/CBD spray in combination with omeprazole had a
CV% range of 40-67% for combination treatment and 48-
69% for THC/CBD spray alone for CBD and 11-OH-THC.
The CV% range for THC was higher at 74-98% for THC/
CBD spray alone compared to 43-64% when administered
in combination with omeprazole.
Table 2 Summary of pharmacokinetic parameters of THC,
CBD and 11-OH-THC after a single dose of THC/CBD
(4 sprays) alone or in combination with ketoconazole
Parameter THC/CBD spray
alone (n = 12)
THC/CBD spray and
ketoconazole (n = 11)
THC
AUC(0-t) (h*ng/mL) 8.19 (5.67) 15.38 (13.43)
AUC(0-inf) (h*ng/mL) 9.22 (5.94)
a 16.76 (13.80)
Cmax (ng/mL) 2.65 (1.32) 3.36 (1.65)
Tmax (h) 1.50 (0.75-6.00) 1.75 (1.00-3.00)
Kel (h-1) 0.258 (0.092)a 0.189 (0.078)
t½ (h) 3.07 (1.31)
a 4.43 (2.19)
CL/F (L/h) 1504 (688)a 920 (450)
Varea/F (L) 6328 (4164)a 5111 (2221)
CBD
AUC(0-t) (h*ng/mL) 1.82 (1.03) 4.83 (2.01)
AUC(0-inf) (h*ng/mL) 3.54 (0.80)
b 6.50 (2.23)c
Cmax (ng/mL) 0.66 (0.37) 1.25 (0.51)
Tmax (h) 1.38 (0.75-6.00) 1.75 (1.00-2.52)
Kel (h-1) 0.122 (0.111)b 0.143 (0.066)c
t½ (h) 7.81 (3.00)
b 6.54 (4.59)c
CL/F (L/h) 2998 (896)b 1731 (650)c
Varea/F (L) 31994 (12794)b 14349 (7076)c
11-OH-THC
AUC(0-t) (h*ng/mL) 21.78 (11.34) 84.34 (40.18)
AUC(0-inf) (h*ng/mL) 27.13 (13.34)
d 95.26 (48.93)
Cmax (ng/mL) 3.59 (1.67) 10.92 (3.83)
Tmax (h) 1.50 (1.00-6.00) 2.25 (1.50-4.13)
Kel (h-1) 0.076 (0.014)d 0.095 (0.016)
t½ (h) 9.51 (2.18)
d 7.48 (1.39)
Data presented are mean and (SD) except for Tmax where median and range
are shown, a n=11; bn=9; cn=10; dn=11.
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A summary of all treatment-emergent AEs (TEAEs) oc-
curring in one or more subject is presented in Table 5.
With the exception of the THC/CBD spray plus ketoco-
nazole study group, all study medication was generally
well tolerated by subjects.
The most common TEAEs with THC/CBD spray alone
were somnolence and headache. For THC/CBD spray
plus rifampicin, these were rhinitis, headache and mal-
aise; but none was considered related to THC/CBD
spray, all were of mild severity, and none was reported
with a subject incidence greater than one. Subjects re-
ceiving THC/CBD spray plus ketoconazole reported the
greatest subject incidence (100%) of TEAEs in the study,
with a total of 35 TEAEs reported in 11 subjects. The
majority of these were of the system organ class (SOC)
nervous system disorders. Similarly, the majority ofTEAEs reported by subjects receiving THC/CBD spray
plus omeprazole were also nervous system disorders, the
most common being dizziness.
No other clinically significant abnormalities for labora-
tory safety measurements or ECG parameters were
reported during the study.
Discussion
This study investigated the effects of the known CYP450
inhibitors or inducers rifampicin, ketoconazole and omep-
razole, on the PK and safety profiles of THC/CBD spray.
Rifampicin and THC/CBD spray
When prescribing drugs that share the CYP3A4 path-
way, plasma levels should be periodically monitored,
otherwise it is possible that drug levels may reach a toxic
state that can manifest as serious medical events if one
of them is a CYP3A4 inhibitor (such as ketoconazole)
(Ogu & Maxa 2000). If one of the drugs is a CYP3A4 in-
ducer, such as rifampicin, then the effectiveness of the
other drug might be compromised following a more
rapid reduction than usual of the plasma level. As such,
investigating the PKs of THC/CBD spray in combination
with a CYP3A4 inducer was of high clinical importance.
Rifampicin was chosen as it has been extensively used in
clinical studies as a prototypical inducer of CYP3A4
(Division of Clinical Pharmacology 2012), but it is also a
moderate CYP2C19 inducer (Federal Drug Association
2012). Overall exposure to repeated daily doses of rifam-
picin for 10 days, followed by a single dose of THC/CBD
spray (4 sprays), reduced the mean plasma levels of
THC and CBD, and most of all, 11-OH-THC, as com-
pared with levels observed when THC/CBD spray alone
was administered. While the magnitude of the reduction
in the plasma levels of the three analytes was within the
range of inter-individual variation observed with THC/
CBD spray alone, suggesting that significant induction of
CYP3A4 would lead to only a slight reduction in expos-
ure to CBs, intra-subject variability must also be consid-
ered. For example, should a subjects whose symptoms
are controlled by a daily dose of seven sprays of THC/
CBD spray experience a reduction in plasma levels of
CBs of 1/3 in the presence of a CYP3A4 inducer, they
would need to increase their dose to experience the
same efficacy of THC/CBD spray. The effect of rifampi-
cin on the group mean Cmax and AUC of CBD and THC
was consistent with the inducing effects of rifampicin on
the CYP3A4 isoenzyme (Michalets 1998). Both CBD and
THC exposure decreased when rifampicin was adminis-
tered with THC/CBD spray and the apparent clearance
for these analytes increased after multiple dose adminis-
tration of rifampicin. Although an increase in exposure
of the 11-OH-THC metabolite was expected due to an-
ticipated conversion of THC to 11-OH-THC via
Table 3 Summary of pharmacokinetic parameters of THC,
CBD and 11-OH-THC after a single dose of THC/CBD
(4 sprays) alone or in combination omeprazole
Parameter THC/CBD spray alone
(n = 12)
THC/CBD spray and
omeprazole (n = 12)
THC
AUC(0-t) (h*ng/mL) 8.76 (8.62) 7.41 (4.75)
AUC(0-inf) (h*ng/mL) 9.39 (8.81) 8.10 (4.78)
Cmax (ng/mL) 2.50 (1.85) 2.48 (1.06)
Tmax (h) 1.25 (0.77-3.02) 1.25 (1.00-1.75)
Kel (h-1) 0.305 (0.109) 0.357 (0.218)
t½ (h) 2.65 (1.25) 2.37 (0.92)
CL/F (L/h) 2161 (1990) 2284 (2520)
Varea/F (L) 6889 (5296) 6052 (3384)
CBD
AUC(0-t) (h*ng/mL) 1.83 (1.19) 2.25 (1.51)
AUC(0-inf) (h*ng/mL) 3.00 (1.43)
a 3.33 (1.77)
Cmax (ng/mL) 0.63 (0.43) 0.73 (0.30)
Tmax (h) 1.15 (0.50-3.02) 1.25 (0.48-1.75)
Kel (h-1) 0.224 (0.158)a 0.210 (0.114)
t½ (h) 5.22 (4.51)
a 5.46 (6.13)
CL/F (L/h) 4741 (3845)a 4772 (4550)
Varea/F (L) 26298 (14532)a 24757 (16311)
11-OH-THC
AUC(0-t) (h*ng/mL) 21.52 (14.76) 17.69 (9.05)
AUC(0-inf) (h*ng/mL) 24.17 (16.47) 19.80 (9.74)
Cmax (ng/mL) 3.48 (2.27) 2.84 (1.40)
Tmax (h) 2.00 (1.25-3.02) 1.52 (1.23-2.50)
Kel (h-1) 0.114 (0.062) 0.095 (0.029)
t½ (h) 7.30 (2.87) 7.98 (2.82)
Data presented are mean and (SD) except for Tmax where median and range
are shown, an=11.
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exposure was observed, suggesting that CYP3A4 is also
involved in the further metabolism of the primary me-
tabolite, 11-OH-THC. A suggested mechanism for this
effect is that increased CYP3A4 activity induced by ri-
fampicin induced further metabolism of 11-OH-THC,
causing a reduced plasma level of 11-OH-THC. This is
the first investigation in humans to identify CYP3A4 as a
significant mediator of 11-OH-THC metabolism, an inter-
esting finding for this psychoactive THC metabolite.
Ketoconazole and THC/CBD spray
Similarly, the effects of the potent CYP3A4 inhibitor ke-
toconazole on the PKs of THC/CBD spray were also in-
vestigated. For both THC and CBD, there was an
increase in mean Cmax and AUC following THC/CBD
spray administration after 5-day period of dailyadministration of ketoconazole. These increases in mean
values were considerably less than the range of inter-
subject variability for the same parameters. However,
intra-subject variability must also be considered, in that
should an individual experienced enhanced plasma levels
of CBs in the presence of a CYP3A4 inhibitor, then their
daily dose of THC/CBD spray would need to be reduced
accordingly in order to balance the efficacy of the com-
pound against any adverse effects that may occur at
higher doses.
For 11-OH-THC, the Cmax was 3.1-times higher after
CYP3A4 inhibition by ketoconazole, and the AUC was
3.8-times higher, confirming that 11-OH-THC is likely
to be metabolized predominantly by CYP3A4. The effect
of ketoconazole on the group mean Cmax and AUC of
CBD and THC was consistent with the inhibitory effects
of ketoconazole on the CYP3A4 isoenzyme. Both CBD
and THC exposure increased when THC/CBD spray
was administered with ketoconazole and the apparent
clearance for CBD and THC decreased after multiple
dose administration of ketoconazole. Although a de-
crease in exposure of the 11-OH-THC metabolite was
expected due to inhibition of the conversion of THC to
11-OH-THC via CYP3A4, a significant increase in me-
tabolite exposure was observed which again suggests
CYP3A4 is involved in the metabolism of the metabolite,
11-OH-THC.
Omeprazole and THC/CBD spray
To investigate the potential interaction of THC/CBD
spray with a CYP2C19 inhibitor, omeprazole was emplo-
yed. In contrast to rifampicin and ketoconazole, co-
administration of THC/CBD spray with omeprazole had
no apparent affect the group mean Cmax or AUC results
for any of the analytes. Any slight differences group
mean AUC and Cmax values for all three analytes were
non-significant and well within the range of inter-
individual variation observed with THC/CBD spray
alone. Furthermore, the apparent clearance for THC and
CBD was not changed between THC/CBD spray alone
versus THC/CBD spray and omeprazole treatments.
However, a decrease in exposure to 11-OH-THC was
observed following co-administration of omeprazole
with THC/CBD spray. Nevertheless, examining the indi-
vidual exposure data, no clear conclusion could be
drawn with respect to any effect of omeprazole. These
findings suggest that THC, CBD are not substrates for
the CYP2C19 isoenzyme.
Safety and tolerability
THC/CBD spray was generally well tolerated when given
alone, illustrated by the fact that there were no serious
AEs during the study. The majority of TEAEs were mild
in severity and, as expected, of the SOC of nervous
Table 4 Point estimate and 90% confidence interval for the geometric mean ratios of Cmax, AUC(0-t) and AUC(0-inf) for
THC/CBD spray in combination with rifampicin, ketoconazole and omeprazole
90% confidence limits
Analyte/PK variable Number of subjects Estimate Lower Upper
Rifampicin and THC/CBD spray
THC/Cmax 12 0.614 0.525 0.719
THC/AUC(0-t) 12 0.711 0.617 0.820
THC/AUC(0-inf) 11 0.761 0.667 0.868
CBD/Cmax 12 0.480 0.420 0.550
CBD/AUC(0-t) 12 0.381 0.274 0.529
CBD/AUC(0-inf) 10 0.422 0.265 0.673
11-OH-THC/Cmax 12 0.140 0.120 0.163
11-OH-THC/AUC(0-t) 12 0.099 0.088 0.113
11-OH-THC/AUC(0-inf) 11 0.131 0.115 0.150
Ketoconazole and THC/CBD spray
THC/Cmax 11 1.252 1.043 1.503
THC/AUC(0-t) 11 1.770 1.385 2.263
THC/AUC(0-inf) 10 1.840 1.446 2.342
CBD/Cmax 11 1.961 1.497 2.569
CBD/AUC(0-t) 11 2.715 2.047 3.601
CBD/AUC(0-inf) 9 1.923 1.560 2.370
11-OH-THC/Cmax 11 3.074 2.705 3.493
11-OH-THC/AUC(0-t) 11 3.823 3.405 4.292
11-OH-THC/AUC(0-inf) 10 3.616 3.181 4.111
Omeprazole and THC/CBD spray
THC/Cmax 12 1.125 0.842 1.501
THC/AUC(0-t) 12 0.964 0.643 1.445
THC/AUC(0-inf) 12 0.962 0.668 1.386
CBD/Cmax 12 1.320 0.938 1.859
CBD/AUC(0-t) 12 1.326 0.756 2.325
CBD/AUC(0-inf) 11 1.096 0.745 1.611
11-OH-THC/Cmax 12 0.866 0.700 1.073
11-OH-THC/AUC(0-t) 12 0.869 0.629 1.201
11-OH-THC/AUC(0-inf) 12 0.869 0.641 1.179
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http://www.springerplus.com/content/2/1/236system disorders, with somnolence being the most
commonly reported. While the exposure to THC/CBD
spray was lower than usual in chronic patients, the
administration procedure did not follow the slow up-
titration process that takes 4-5 days to reach a dose
of 4 sprays/day (and goes on for 7-8 days to reach
the average 6-7 sprays/day dose, and up to 14 days to
reach the maximum dose of 12 sprays/day). As such,
the incidence of AEs in the SOC of nervous disorders
in the current study is not surprising. A review of
collated results from initial randomized-controlled
clinical trials with THC/CBD spray involving 930
patients demonstrated that the most frequentlyreported AEs (incidence >10%) were dizziness (28%),
diarrhoea (13%), fatigue (11%) and nausea (11%)
(Constantinescu & Sarantis 2006). Recent publications
also demonstrate that AEs the SOC of nervous systems
disorders were among the commonly occurring AEs
reported with THC/CBD spray use (Johnson et al. 2012;
Langford et al. 2013).
No difference was observed in the proportions of sub-
jects reporting AEs upon co-administration of THC/
CBD spray with rifampicin or omeprazole compared
with THC/CBD spray alone. Again, all AEs were of mild
severity, with headache and dysguesia being the most
commonly reported for THC/CBD spray and rifampicin
Table 5 Treatment emergent adverse events with an incidence >1
Primary system organ class Preferred term* No. of subjects (%) No. of subjects (%) No. of subjects (%)
THC/CBD spray (n = 36)
Psychiatric disorders
Euphoric mood 2 (6) - -
Nervous system disorders
Dizziness 2 (6) - -
Dizziness postural 3 (8) - -
Headache 5 (14) - -
Somnolence 11 (31) - -
Gastrointestinal disorders
Nausea 2 (6) - -
Rifampicin (n = 12) THC/CBD spray and Rifampicin (n = 12) THC/CBD spray (n = 12)
Nervous system disorders
Dysgeusia 1 (8) 0 1 (8)
Headache 0 1 (8) 1 (8)
Somnolence 0 0 2 (17)
Ketoconazole (n = 12) THC/CBD spray and Ketoconazole (n = 11) THC/CBD spray (n = 12)
Nervous system disorders
Somnolence 0 4 (36) 4 (33)
Dizziness 0 3 (27) 2 (17)
Lethargy 0 3 (27) 0
Dysgeusia 0 2 (18) 0
Headache 0 2 (18) 0
Somnolence 0 1 (9) 1 (8)
Psychiatric disorders
Euphoric mood 0 7 (64) 0
Anxiety 0 1 (9) 1 (8)
Disorientation 0 1 (9) 1 (8)
Omeprazole (n = 12) THC/CBD spray and Omeprazole (n = 12) THC/CBD spray (n = 12)
Nervous system disorders
Dizziness 0 3 (25) 0
Dizziness postural 0 0 2 (17)
Headache 1 (8) 0 4 (33)
Somnolence 0 2 (17) 5 (42)
Gastrointestinal disorders
Dry mouth 0 2 (17) 1 (8)
*MedDRA version 10.0.
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THC/CBD spray and omeprazole.
Although all subjects receiving THC/CBD spray and
ketoconazole experienced AEs, this combination was still
relatively well tolerated, and all but one AE was of mild
severity. The majority of TEAEs were classed as nervous
system disorders, including somnolence and dizziness
which occurred at the same incidence as with THC/CBDspray alone. However, there was an increased incidence
of euphoric mood, lethargy, dygeusia and headache
when THC/CBD spray was given in combination with
ketoconazole. Only one event was classed as moderate
in terms of severity (anxiety) and the event resolved
without intervention. All other events were of mild
severity. Notably in this group, all subjects had
increases in Cmax for 11-OH-THC, and seven had an
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an increase in AUC. Taking into account the increase
in exposure after combined administration compared
to THC/CBD spray alone, it is possible that the difference
in PKs may account for the increase in CNS-type
AEs observed.
Study limitations
There were a number of limitations to this study. Kel
was estimated over a short sampling period (less than
two t1/2s) for the majority of profiles in this study and
the regression had low precision in some profiles. AUC
(0-inf ) had an extrapolated area which was larger than
20% for some profiles. However, despite these limita-
tions, the AUC(0-inf ) and the AUC(0-t) were in agreement,
and the statistical results are thus considered reliable.
Further consistency and validity of the study is demon-
strated by the similarity of the PK exposure parameters
following a single dose of THC/CBD spray in the ab-
sence of any inducer or inhibitor, which are in good
agreement with the PK data provided in a previous clin-
ical study performed by the authors (ref PK study). The
inter-subject variability was substantial and greater than
the difference in exposure means before and after rifampi-
cin, ketoconazole, or omeprazole treatment, suggesting
that any effect of other medications metabolized by rele-
vant CYP enzymes on THC/CBD spray is likely to be
within the normal range of variation. However, there was
generally a similar variability in the group mean primary
PK parameters between the THC/CBD spray alone and
the THC/CBD spray plus inducer or inhibitor treatments.
Doses of THC/CBD (4 sprays instead the average 6-8
sprays/day) and intake patterns (4 sprays in a row in-
stead of evenly distributed through the day) were not
equivalent to those in the approved label. However, dur-
ing a phase IIb dose ranging study in cancer patients
with pain, in the low dose THC/CBD spray (1-4 sprays)
group, over 90% of patients titrated to a dose of 3 or 4
sprays, leading to the conclusion that a minimal effective
dose was 3 sprays per day (Porteney et al. 2012).
Additionally, efficacy was observed in the low dose
group, reaching statistical significance for the continuous
response analysis (pain 0-10 Numerical Rating Scale
score) and for the mean change from baseline in score,
demonstrating that 4 daily sprays is a clinically relevant
dose (Porteney et al. 2012). Distributing the dose through-
out the day in the current study would have given a very
different PK profile, and would not have been a suitable
approach for the current study. Additionally, during a
previous Phase I pharmacokinetics study, doses of 2
daily sprays of THC/CBD spray gave low Cmax values
(Stott et al. 2012). As such, a dose of 4 daily sprays
was chosen to give good plasma concentration over
time curves.Conclusions
In conclusion, inhibition of CYP2C19 by omeprazole did
not significantly alter the PK of THC/CBD spray
suggesting that THC, CBD and 11-OH-THC are not
substrates for this isoenzyme at the clinically relevant
dose of THC/CBD spray investigated. The CYP3A4 in-
ducer rifampicin caused a decrease in exposure to all
three analytes, although not extreme and within the nat-
ural range of variation between subjects. Conversely, the
CYP3A4 inhibitor ketoconazole caused increased expos-
ure to all analytes, suggesting that THC, CBD and
11-OH-THC all are substrates for this isoenzyme. More-
over, the findings with rifampicin and ketoconazole sug-
gest that CYP3A4 is involved in the metabolism of
11-OH-THC. On the basis of these findings, there is
likely to be little impact on other drugs metabolized by
CYP enzymes on the PK parameters of THC/CBD spray,
but potential effects should be taken into consideration
when co-administering THC/CBD spray with com-
pounds which share the CYP3A4 pathway. THC/CBD
spray was also well tolerated in healthy subjects both
alone and in combination with rifampicin, ketoconazole
and omeprazole.Ethical standards
The current study was approved by Guy's Research Eth-
ics Committee, and was conducted in accordance with
the International Conference on Harmonisation guide-
lines on Good Clinical Practice and the ethical principles
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